165 related articles for article (PubMed ID: 7949188)
1. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin.
Watanabe T; Hotta T; Ichikawa A; Kinoshita T; Nagai H; Uchida T; Murate T; Saito H
Blood; 1994 Nov; 84(9):3158-65. PubMed ID: 7949188
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the MDM2 oncogene in leukemia and lymphoma.
Watanabe T; Ichikawa A; Saito H; Hotta T
Leuk Lymphoma; 1996 May; 21(5-6):391-7, color plates XVI following 5. PubMed ID: 9172803
[TBL] [Abstract][Full Text] [Related]
3. Rearrangement and expression of MDM2 oncogene in chronic lymphocytic leukemia.
Huang YQ; Raphael B; Buchbinder A; Li JJ; Zhang WG; Friedman-Kien AE
Am J Hematol; 1994 Oct; 47(2):139-41. PubMed ID: 8092130
[TBL] [Abstract][Full Text] [Related]
4. MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas.
Maestro R; Gloghini A; Doglioni C; Gasparotto D; Vukosavljevic T; De Re V; Laurino L; Carbone A; Boiocchi M
Blood; 1995 Jun; 85(11):3239-46. PubMed ID: 7756655
[TBL] [Abstract][Full Text] [Related]
5. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.
Matolcsy A; Chadburn A; Knowles DM
Am J Pathol; 1995 Jul; 147(1):207-16. PubMed ID: 7541611
[TBL] [Abstract][Full Text] [Related]
6. Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, sIg+ B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias.
Golay J; Luppi M; Songia S; Palvarini C; Lombardi L; Aiello A; Delia D; Lam K; Crawford DH; Biondi A; Barbui T; Rambaldi A; Introna M
Blood; 1996 Mar; 87(5):1900-11. PubMed ID: 8634438
[TBL] [Abstract][Full Text] [Related]
7. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities.
Møller MB; Nielsen O; Pedersen NT
Mod Pathol; 1999 Nov; 12(11):1010-6. PubMed ID: 10574597
[TBL] [Abstract][Full Text] [Related]
8. Bcl-2 rearrangements with breakpoints in both vcr and mbr in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia.
Merup M; Spasokoukotskaja T; Einhorn S; Smith CI; Gahrton G; Juliusson G
Br J Haematol; 1996 Mar; 92(3):647-52. PubMed ID: 8616030
[TBL] [Abstract][Full Text] [Related]
9. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma.
Møller MB; Nielsen O; Pedersen NT
Histopathology; 2002 Oct; 41(4):322-30. PubMed ID: 12383214
[TBL] [Abstract][Full Text] [Related]
10. Rearrangement of the 5' cluster region of the BCL2 gene in lymphoid neoplasm: a summary of nine cases.
Yabumoto K; Akasaka T; Muramatsu M; Kadowaki N; Hayashi T; Ohno H; Fukuhara S; Okuma M
Leukemia; 1996 Jun; 10(6):970-7. PubMed ID: 8667654
[TBL] [Abstract][Full Text] [Related]
11. S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia.
Liu L; Fan L; Fang C; Zou ZJ; Yang S; Zhang LN; Li JY; Xu W
Cancer Sci; 2012 Dec; 103(12):2056-63. PubMed ID: 22937789
[TBL] [Abstract][Full Text] [Related]
12. Detection of p53 mutations in B cell non-Hodgkin's lymphoma cell lines.
Li CC; O'Connell CD; Beckwith M; Longo DL
Leukemia; 1995 Apr; 9(4):650-5. PubMed ID: 7723400
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene.
Zhou M; Yeager AM; Smith SD; Findley HW
Blood; 1995 Mar; 85(6):1608-14. PubMed ID: 7888679
[TBL] [Abstract][Full Text] [Related]
14. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma.
Shibagaki I; Tanaka H; Shimada Y; Wagata T; Ikenaga M; Imamura M; Ishizaki K
Clin Cancer Res; 1995 Jul; 1(7):769-73. PubMed ID: 9816044
[TBL] [Abstract][Full Text] [Related]
15. Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias.
Wojcik I; Szybka M; Golanska E; Rieske P; Blonski JZ; Robak T; Bartkowiak J
Neoplasma; 2005; 52(4):318-24. PubMed ID: 16059649
[TBL] [Abstract][Full Text] [Related]
16. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
[TBL] [Abstract][Full Text] [Related]
17. The expression of the MDM2 gene, a p53 binding protein, in thyroid carcinogenesis.
Zou M; Shi Y; al-Sedairy S; Hussain SS; Farid NR
Cancer; 1995 Jul; 76(2):314-8. PubMed ID: 8625108
[TBL] [Abstract][Full Text] [Related]
18. Genetic analysis of Raf1, Mdm2, c-Myc, Cdc25a and Cdc25b proto-oncogenes in 2',3'-dideoxycytidine- and 1,3-butadiene-induced lymphomas in B6C3F1 mice.
Zhuang S; Söderkvist P
Mutat Res; 2000 Jul; 452(1):19-26. PubMed ID: 10894886
[TBL] [Abstract][Full Text] [Related]
19. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N
J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248
[TBL] [Abstract][Full Text] [Related]
20. Alterations of the p53, Rb and MDM2 genes in osteosarcoma.
Miller CW; Aslo A; Won A; Tan M; Lampkin B; Koeffler HP
J Cancer Res Clin Oncol; 1996; 122(9):559-65. PubMed ID: 8781571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]